Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasms 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Leukemia, B-Cell 1Hodgkin Disease 1

Interventions

Cyclophosphamide 5Vincristine 3Prednisolone 3Peripheral Blood Stem Cell Transplantation 3Methylprednisolone 3Doxorubicin 3Cyclosporine 3Antilymphocyte Serum 3fludarabine phosphate 2Psychiatric Rehabilitation 2Mycophenolic Acid 2Melphalan 2Gemcitabine 2Flow Cytometry 2Cytarabine 2Cisplatin 2Carboplatin 2Busulfan 2Alemtuzumab 2sargramostim 1romidepsin 1motesanib diphosphate 1lorlatinib 1etoposide phosphate 1carbendazim 1Whole-Body Irradiation 1Vindesine 1Vinblastine 1Thiotepa 1Therapeutics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lymphoma, Large-Cell, Anaplastic × Biological Products × Clear all
NCT03383965 2017-12-27

CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas

Immune Cell, Inc.

Phase 1 Unknown
20 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡